Arvinas Inc ARVN shares are trading higher by 11.2% to $24.32 Monday morning after the company announced an oversubscribed $350 million private placement.
The sale involves both common stock and pre-funded warrants at specific prices, with each warrant exercisable immediately. The company plans to use the funds to support its clinical programs, preclinical pipeline and general operations.
See Also: Why Biodexa Pharmaceuticals Stock Is Skyrocketing
The placement is set to close on November 28, pending standard closing conditions and is compliant with Nasdaq regulations. The offering was co-led by EcoR1 Capital and entities managed by RTW Investments, LP and involved several new and existing investors.
BofA Securities, Inc. and Goldman Sachs & Co. LLC served as joint lead placement agents for Arvinas in this transaction.
According to data from Benzinga Pro, ARVN has a 52-week high of $42.52 and a 52-week low of $13.57.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
